VivoSeq
Other

Leflunomide

0

Pipeline Programs↗

1

Active Trials↗

2

Companies Involved↗

Leflunomide is an early-stage landscape with 0 programs across 2 companies. The most active players are Teva, Par Pharmaceutical, Inc..

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

75/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Teva logo

Teva

0 programs

PreclinicalP

Par Pharmaceutical, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

6

clinical trials

Completed3 · 50%
Recruiting1 · 17%
Terminated1 · 17%
Unknown status1 · 17%

Clinical Trials

Trial Activity

6 trials

Leflunomide for Henoch-Schonlein Purpura
Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·N/A·NCT05937880·36 enrolled
Leflunomide 20 mg Tablets, Non-Fasting
Completed·Teva logoTeva·Phase 1·NCT00834405·37 enrolled
Bioavailability Study of Leflunomide Tablets Under Fed Conditions
Completed·PPar Pharmaceutical, Inc.·Phase 1·NCT00653003·62 enrolled
Effect of Leflunomide on T Cell Proliferation in HIV-Infected Patients
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00101374·41 enrolled
Leflunomide Treatment for MEN1 Patients - the LUMEN1 Trial
Terminated·UUniversity Hospital, Basel, Switzerland·N/A·NCT05605587·3 enrolled
Leflunomide Treatment for IgG4-RD
Unknown status·PPeking Union Medical College Hospital·N/A·NCT03715699·70 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)